NOXXON Presents Final Clinical Data From Phase 1/2 NOX-A12 / Keytruda Combination Trial in Colorectal and Pancreatic Cancer at the ESMO Virtual Congress 2020

Nachrichtenquelle: Business Wire (engl.)
17.09.2020, 09:00  |  112   |   |   

Regulatory News:

NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), presents today a poster with the final clinical results from the Phase 1/2 study with CXCL12 inhibitor, NOX-A12, and pembrolizumab in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer at the European Society for Medical Oncology (ESMO) Virtual Congress 2020. The enhanced immune response and long survival times for certain late-stage patients combined with the good overall safety profile confirmed in the final data support further development of the combinations containing NOX-A12 plus pembrolizumab and established standard of care regimens in earlier lines of therapy. The poster presentation is complemented by a video presentation with remarks highlighting the trial’s most significant data provided by Dr. Niels Halama from the National Center for Tumor Diseases (NCT) in Heidelberg, Germany, the first author of the poster presentation and the principal investigator of the trial.

In this trial, we observed a number of patients – 25% of the total – who experienced disease stabilization and many with prolonged survival also during the follow-up period, which is particularly noteworthy in patients at such a late-stage of disease progression. In fact, we saw multiple cases of 4th line pancreatic cancer patients, who did not respond at all to their prior therapy, surviving for more than one year,” commented Dr. Niels Halama.

The patients in this study were, on average, receiving their 6th line of therapy in colorectal cancer and their 4th line of therapy in pancreatic cancer. In addition, all patients had liver metastases and, in 95% of cases, were completely non-responsive to their last therapy before entering this study. As such, the data from this study provide signals that support a beneficial impact of the combination of NOX-A12 with pembrolizumab for patients with extremely limited options. Thus, we are planning to advance NOX-A12 into the next stage of clinical development in at least one of these indications,” added Dr. Jarl Ulf Jungnelius, Senior Medical Advisor of NOXXON.

Seite 1 von 3
NOXXON Pharma Aktie jetzt ab 0€ handeln - auf

Diesen Artikel teilen

0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren



Meistgelesene Nachrichten des Autors


Diskussionen zu den Werten